What is the share price of Hemo Organic Ltd (HEMORGANIC) today?
The share price of HEMORGANIC as on 15th July 2025 is ₹10.03. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Hemo Organic Ltd (HEMORGANIC) share?
The past returns of Hemo Organic Ltd (HEMORGANIC) share are- Past 1 week: 3.95%
- Past 1 month: -8.35%
- Past 3 months: 1.01%
- Past 6 months: -3.56%
- Past 1 year: -9.15%
- Past 3 years: -72.33%
- Past 5 years: -17.65%
What are the peers or stocks similar to Hemo Organic Ltd (HEMORGANIC)?
The peers or stocks similar to Hemo Organic Ltd (HEMORGANIC) include:What is the market cap of Hemo Organic Ltd (HEMORGANIC) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hemo Organic Ltd (HEMORGANIC) is ₹3.46 Cr as of 15th July 2025.What is the 52 week high and low of Hemo Organic Ltd (HEMORGANIC) share?
The 52-week high of Hemo Organic Ltd (HEMORGANIC) is ₹15.25 and the 52-week low is ₹8.05.What is the PE and PB ratio of Hemo Organic Ltd (HEMORGANIC) stock?
The P/E (price-to-earnings) ratio of Hemo Organic Ltd (HEMORGANIC) is 21.64. The P/B (price-to-book) ratio is -11.17.Which sector does Hemo Organic Ltd (HEMORGANIC) belong to?
Hemo Organic Ltd (HEMORGANIC) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Hemo Organic Ltd (HEMORGANIC) shares?
You can directly buy Hemo Organic Ltd (HEMORGANIC) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Hemo Organic Ltd
HEMORGANIC Share Price
10.030.40% (+0.04)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
HEMORGANIC Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
HEMORGANIC Performance & Key Metrics
HEMORGANIC Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 21.64 | -11.17 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.43 | 6.45 | 0.81% |
HEMORGANIC Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
HEMORGANIC Company Profile
Hemo Organic is engaged in manufacturing of ayurvedic medicines.
SUNPHARMA
PE Ratio
36.94
36.94
1Y Return
8.91%
8.91%
Buy Reco %
84.85
84.85
CIPLA
PE Ratio
22.73
22.73
1Y Return
1.73%
1.73%
Buy Reco %
68.75
68.75
TORNTPHARM
PE Ratio
60.29
60.29
1Y Return
16.45%
16.45%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
55.89
55.89
1Y Return
23.38%
23.38%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.40
18.40
1Y Return
7.22%
7.22%
Buy Reco %
48.39
48.39
HEMORGANIC Forecast
HEMORGANIC Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
HEMORGANIC
HEMORGANIC
Income
Balance Sheet
Cash Flow
Annual Normal View
HEMORGANIC Income Statement
HEMORGANIC Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.60 | 0.09 | 0.05 | 0.28 | 0.01 | 0.01 | 0.00 | 0.02 | 2.48 | 2.50 | ||||||||||
Raw Materials | 0.56 | 0.07 | 0.05 | 0.19 | 0.01 | 0.02 | 0.00 | 0.00 | 2.46 | 2.48 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||
| Employee Cost | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | ||||||||||||
| Selling & Administrative Expenses | 0.09 | 0.07 | 0.05 | 0.08 | 0.04 | 0.05 | 0.06 | 0.25 | ||||||||||||
| Operating & Other expenses | 0.00 | 0.08 | 0.06 | 0.02 | 0.00 | -0.01 | 0.00 | 0.02 | ||||||||||||
EBITDA | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.06 | -0.25 | 0.02 | 0.02 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBIT | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.06 | -0.25 | 0.02 | 0.02 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | — | ||||||||||
| PBT | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.06 | -0.27 | 0.02 | 0.02 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.14 | ||||||||||
| Net Income | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.06 | -0.27 | 0.16 | 0.16 | ||||||||||
| EPS | -0.23 | -0.43 | -0.35 | -0.06 | -0.14 | -0.17 | -0.17 | -0.78 | 0.47 | 0.46 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
HEMORGANIC Company Updates
HEMORGANIC Stock Peers
HEMORGANIC Past Performance & Peer Comparison
HEMORGANIC Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Hemo Organic Ltd | 21.64 | -11.17 | — |
| Sun Pharmaceutical Industries Ltd | 36.94 | 5.57 | 0.95% |
| Cipla Ltd | 22.73 | 3.83 | 1.08% |
| Torrent Pharmaceuticals Ltd | 60.29 | 15.18 | 0.94% |
HEMORGANIC Stock Price Comparison
Compare HEMORGANIC with any stock or ETFCompare HEMORGANIC with any stock or ETF
HEMORGANIC
HEMORGANIC Holdings
HEMORGANIC Shareholdings
HEMORGANIC Promoter Holdings Trend
HEMORGANIC Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
HEMORGANIC Institutional Holdings Trend
HEMORGANIC Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.17%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
HEMORGANIC Shareholding Pattern
HEMORGANIC Shareholding Pattern
HEMORGANIC Shareholding History
HEMORGANIC Shareholding History
Foreign Institutions
smallcases containing HEMORGANIC stock
smallcases containing HEMORGANIC stock
Looks like this stock is not in any smallcase yet.
HEMORGANIC Events
HEMORGANIC Events
HEMORGANIC Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HEMORGANIC has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
HEMORGANIC Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HEMORGANIC has not given any dividends in last 5 years
HEMORGANIC Dividends
HEMORGANIC Dividends
Hmm, looks like data is unavailable here. Please come back after some timeHEMORGANIC Stock News & Opinions
HEMORGANIC Stock News & Opinions
Articles & Videos
Earnings
Hemo Organic reports standalone net profit of Rs 0.37 crore in the March 2025 quarter
Net profit of Hemo Organic reported to Rs 0.37 crore in the quarter ended March 2025 as against net loss of Rs 0.23 crore during the previous quarter ended March 2024. Sales rose 11950.00% to Rs 2.41 crore in the quarter ended March 2025 as against Rs 0.02 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 0.16 crore in the year ended March 2025 as against net loss of Rs 0.26 crore during the previous year ended March 2024. Sales rose 11950.00% to Rs 2.41 crore in the year ended March 2025 as against Rs 0.02 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2.410.02 11950 2.410.02 11950 OPM %5.81-1050.00 --2.07-1200.00 - PBDT0.23-0.23 LP 0.02-0.26 LP PBT0.23-0.23 LP 0.02-0.26 LP NP0.37-0.23 LP 0.16-0.26 LP Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Hemo Organic to convene board meeting
Hemo Organic will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Hemo Organic reports standalone net loss of Rs 0.13 crore in the December 2024 quarter
Net loss of Hemo Organic reported to Rs 0.13 crore in the quarter ended December 2024. There were no net profit/loss reported during the previous quarter ended December 2023. There were no Sales reported in the quarter ended December 2024 and during the previous quarter ended December 2023.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Hemo Organic to announce Quarterly Result
Hemo Organic will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Hemo Organic to hold board meeting
Hemo Organic will hold a meeting of the Board of Directors of the Company on 26 December 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Hemo Organic reports standalone net loss of Rs 0.08 crore in the September 2024 quarter
Net loss of Hemo Organic reported to Rs 0.08 crore in the quarter ended September 2024 as against net profit of Rs 0.01 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Hemo Organic schedules AGM
Hemo Organic announced that the 32th Annual General Meeting (AGM) of the company will be held on 11 September 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Earnings
Hemo Organic reports standalone nil net profit/loss in the June 2024 quarter
Hemo Organic reported no net profit/loss in the quarter ended June 2024 as against net loss of Rs 0.04 crore during the previous quarter ended June 2023. There were no Sales reported in the quarter ended June 2024 and during the previous quarter ended June 2023.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Hemo Organic to declare Quarterly Result
Hemo Organic will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
11 months agoCapital Market - Live
Hemo Organic reports standalone nil net profit/loss in the December 2022 quarter
2 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of 54.69%, vs industry avg of 10.15%
Over the last 5 years, market share stayed at 0%